$LEADS BIOLABS-B(09887.HK) got 3 lots and sold 2 lots, thanks to Longbridge and the new stock.
Overview
LEADS BIOLABS-B (9887)
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs wor...
- Open
- 35.000
- High
- 35.000
- Low
- 32.740
- Prev. Close
- 35.120
- Volume
- 1.17M
- Turnover
- 38.97M
- Avg Price
- 33.269
- Bid/Ask Ratio
- 70.37%
- Amplitude
- 6.44%
- 52wk High
- 97.500
- Volume Ratio
- 1.05
- Turnover Ratio
- 0.59%
- 52wk Low
- 32.740
- HK Mkt Cap
- 6.57B
- Market CapHKD
- 6.62B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.55
- EPSDynamic
- -2.57
- EPSStatic
- --
- BVPS
- 5.39
- P/B
- 6.17
- HK Shares
- 197.67M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 198.89M
- Min lot size
- 100
- Currency
- HKD
LEADS BIOLABS-B Analyst Rating
View moreForecast & Rating
Oct 15, 2026- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 4
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Extending the prior session's near-7% slide, the stock closed down 5.30% at HK$33.26 after spiking and fading: it opened at HK$35.00 and sank to a fresh 52-week low of HK$32.74 by 10:16 BJ, then traded narrowly around HK$33.0 through the afternoon on 1.17 million shares worth about HK$38.97 million. A dense run of clinical updates, including LBL-024's 8.7-month median survival in late-line EP-NEC, LBL-034's 21.8-month mPFS in RRMM, the first SLE patient dosed with LBL-047 and a second FDA Fast Track, failed to reverse the decline, while Q2 revenue of HK$20.77 million came alongside a HK$128.17 million net loss that widened 28.5% year-on-year at a -617% net margin. The shares are down 34.14% year-to-date, 65.89% below the 15 April high of HK$97.5, and sit under the MA20 of HK$37.03 and MA60 of HK$50.59. CLSA nonetheless pointed to improving overseas and domestic trends in China healthcare.
- Nov, 13
维立志博-B 今日冲高回落,以 37.46 港元平开后单边走弱,14:51 下探 34.92 港元,收 35.02 港元、跌约 6.3%,成交 2889 万港元,换手率 0.41%。LBL-024 在胆道癌取得 55% 缓解率、拿到第二项 FDA 快速通道,以及 LBL-047 完成 SLE 首例给药等进展,都未能支撑股价;Q2 2026 净亏损扩大 28.5% 至 1.282 亿港元,收入仅 2077 万港元,EPS -0.6505 港元,对应 PE -22.73、PB 6.52。现价 35.12 港元低于 MA20 37.43 与 MA60 51.31,年内跌 30.46%,较 52 周高点 97.5 港元低 63.98%,距 33.66 港元低点仅 4.34%。CLSA 称中国医疗板块回调是买入机会,不过公司仍处亏损且股价受制于两条均线。
- Nov, 10
Carrying over ESMO pipeline readouts and the first SLE patient dosed with LBL-047, plus a weekly recap showing most brokers rate the stock buy, 9887.HK reversed early weakness, sliding to HK$37.44 in the morning session before an afternoon push to HK$39.80, and closed up 3.71% at HK$39.08 on HK$47.16 million turnover. The 21.8-month median PFS for LBL-034 in relapsed/refractory multiple myeloma remains the main anchor for sentiment. Fundamentals are still at a pre-commercial scale: Q2 revenue of HK$20.77 million against a net loss of HK$128.17 million, 28.5% wider year on year, with loss per share of HK$0.6505. The stock has reclaimed its MA20 of HK$38.22 but sits well below the MA60 of HK$53.09, 59.92% below the April 15 high of HK$97.50 and down 22.61% year to date, though still 16.1% above the November 3 low of HK$33.66. Shareholder Nanjing Lizhi nonetheless trimmed 16,500 shares at about HK$43.67, and a 0.62% turnover rate shows no volume confirmation.
- Nov, 9
Leads Biolabs rose 3.06% to HK$37.68 after opening at HK$37.88, spiking to an intraday high of HK$38.56 at 10:58 in the morning session before fading through the afternoon, following the first systemic lupus erythematosus patient dosed in Part B of the Phase I study of LBL-047, a BDCA2/TACI bifunctional fusion protein, alongside ESMO 2026 data showing 21.8-month mPFS for LBL-034 and 8.7-month median survival for LBL-024. That clinical cadence contrasts with the financials: Q2 2026 revenue was only HK$20.77 million while the net loss widened 28.5% year on year to HK$128.17 million, with ROE at -47.68%. The shares remain below the MA20 of HK$38.54 and the MA60 of HK$53.66, down 25.39% year to date and 61.35% below the 52-week high of HK$97.5, though they sit 11.94% above the 52-week low of HK$33.66 set on 3 November.
- Nov, 6
Leads Biolabs-B closed down 4.19% at HK$36.56 in a spike-and-fade session, having touched HK$37.44 at 09:53 before losing momentum and probing HK$36.20 in the afternoon, staying below the prior close of HK$38.16. The tape continued to absorb October ESMO data, including an 8.7-month median survival for LBL-024 in late-line EP-NEC and a 21.8-month mPFS for LBL-034 in RRMM, plus the first SLE patient dosed in Part B of the Phase I trial of LBL-047, a BDCA2/TACI bifunctional fusion protein; offsetting that, Nanjing Lizhi Enterprise Management Consulting Center sold 16,500 shares at about HK$43.67, and the stock is down 27.6% year to date, 62.5% below its 52-week high of HK$97.50 and just 8.62% above the HK$33.66 low. Q2 EPS of -HK$0.6505 and a net loss of HK$128 million widening 28.5% year on year, with a -617% net margin and a -23.66x PE, leave the price below its MA20 of HK$38.94 and MA60 of HK$54.18; though CLSA sees improving overseas and domestic trends creating opportunity after the China healthcare pullback.
